Core Viewpoint - Federal Pharmaceutical's subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has received clinical trial approval for its innovative drug UBT251 injection for the treatment of moderate to severe obstructive sleep apnea (OSA) in China, indicating a significant advancement in addressing unmet clinical needs in this area [1] Group 1 - UBT251 injection is a multi-target peptide receptor agonist that acts on GLP-1, GIP, and GCG receptors to lower blood sugar and inhibit weight gain, positioning the company favorably in the obesity treatment market [1] - The drug is expected to fill a substantial gap in the treatment of OSA, which has a high unmet clinical demand [1] - UBT251 is also undergoing Phase II clinical trials in China for indications including overweight or obesity, type 2 diabetes, metabolic-associated fatty liver disease, and chronic kidney disease [1] Group 2 - As the first chemically synthesized GLP-1/GIP/GCG tri-target receptor agonist in China, UBT251 enhances the company's position in the research and development of this class of drugs [1] - The company aims to continue its focus on new product development to strengthen its competitiveness and creativity in the biopharmaceutical industry, which is expected to generate greater returns for the company and its shareholders [1]
联邦制药(03933.HK)：UBT251注射液OSA适应症获临床试验默示许可